(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
Optimism in the diabetic foot ulcer sector has accelerated due to the robust results of various treatments undergoing clinical trials. On August 13th, Osiris Therapeutics (OSIR) doubled in price on the news that Grafix, its stem-cell treatment for chronic diabetic foot ulcers (DFU), achieved overwhelmingly effective results in Phase IV studies. The attention generated by this catalyst spilled over to Sanuwave (OTCQB:SNWV), a development stage biotech that is also targeting DFU with its shockwave-based technology device dermaPACE. Following the release, Sanuwave price surged 13% on volume 10x the three month average, a daily capacity the company had not...
Only subscribers can access this article, which is part of the PRO research library covering 3,609 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: